What Exactly is PNC 27:
PNC 27 is an anti-cancer peptide synthetically created to eliminate cancer cells from the body. According to research, when it attaches to cancerous cells, the PNC 27 peptide prompts cell necrosis, causing the cancer cells to die. In addition, research suggests the peptide can kill cancer cells by membranolysis because of the HDM-2 binding domain.
Research also suggests cancers such as breast cancer, melanomas, pancreatic cancer, and leukaemia may be treated with the help of the anti-cancer peptide PNC 27, according to studies conducted on animals.
What is PNC 27 Known For?
Research has shown within a week of taking the peptide, animals studied with PNC-27 peptide showed various impacts in positive outcomes, such as reduced levels of pain. Furthermore, animals show flu-like symptoms when cancer cells die after three weeks of treatment, suggesting that their immune systems are responding. In addition, there is an increase in lactate dehydrogenase and bilirubin at six weeks.
Significant tumour breakdown and softening are not seen until ten weeks after the start of treatment. This is because there could be a growth in the tumour site in some patients. However, the immune system’s response to inflammation is to blame.
Scientists report that after three months, animal subjects show minor cancer-related symptoms and more energy.
According to a 2006 study, PNC-28, structurally and functionally similar to PNC-27, can selectively prevent pancreatic cancer cell proliferation in vivo. A quantity of tumour cell lines was found to be necrotic after exposure to the compound, but the compound did not affect normal cells. As a result, scientists investigated whether the cancer peptide could completely stop the cancer cell growth.
Researchers also discovered that administering the peptide stopped tumour growth for two weeks before and two weeks after.
The tumour size decreased, and the growth rate was slowed when the cancer peptide PNC 27 was administered after the growth of the tumour. As a result, the researchers concluded that this peptide could be effective in killing cancer, particularly when administered instantly to the tumour.
According to a study done in 2014, PNC-27 therapy can cause tumour cell necrosis in a leukaemia cell line that expresses HDM2 on the plasma membrane. This study was conducted in 2014. As a result, scientists built on previous findings that PNC 27 could shrink solid tumours by binding to the HDM-2 protein.
The experiment’s main goal was to see if non-solid tumour cells could express HDM-2 in their membranes like solid tissue cells.
According to the study’s findings, non-solid tumour cells had high levels of HDM2 expression in their cell membranes, and the peptide could cause necrosis just like it could when bound to HDM2.
PNC-27’s side effects and safety are currently unknown due to a shortage of research. On the other hand, animal studies have revealed some adverse effects, such as dehydration, headaches, hypertension, inflammation of the nose, and bleeding in the rectum.
Molar mass: 4029.2
Unit Size: 5mg
Unit Quantity: 1 Vial
Appearance: White Powder
Peptide Purity: >99%